What Limits Water Solubility and pH Drift in Concentrated Poultry Drinking-Water Formulations?

In broiler and layer production systems, the concentrated quinolone premix oral solution is proportioned through in-line medicators at rates that must hold a target final water concentration of 50 mg/L over a three-day dosing window. The liquid concentrate is typically formulated at 100 mg/mL (10% w/v) quinolone base equivalent, using purified water and lactic acid for pH adjustment. The pH is maintained between 3.8 and 4.2 because upward drift above 5.5 precipitates the free-base quinolone as a non-wettable floc, while downward drift below 2.5 accelerates acid-catalysed opening of the piperazinyl ring. Production-scale manufacture begins with a pre-dissolution slurry of the premix in 30–35°C purified water, followed by addition of lactic acid under high-shear mixing at 1,200–1,500 rpm. Nitrogen sparging is applied to maintain dissolved oxygen below 0.5 mg/L, and the solution is filtered through 5 µm polypropylene depth media and then 0.45 µm polypropylene cartridge filters before filling. The container system is selected for low UV transmission: 500 mL, 1 L, and 5 L amber HDPE bottles with polypropylene caps and induction-sealed polyethylene liners. Compliance is anchored to the Table 1 MRL entries for poultry in Regulation (EU) No 37/2010, residue-safety documentation under VICH GL 18, and manufacturing under EudraLex Volume 4 Part 4. A defined limitation is encountered in hard-water districts: if water hardness exceeds 250 mg/L CaCO₃, the diluted solution can form quinolone-calcium chelate precipitates; citric acid is therefore included in the concentrate at 0.5–1.0% w/v to act as a competitive chelator. Published photochemical degradation product data for this specific premix concentrate is limited, so protect-from-light storage below 25°C is placed on the label rather than relying on accelerated photostability extrapolation. The finished dosage form types are concentrated oral solutions for bulk tank or proportioner use in poultry houses.

When the downstream form is a parenteral injectable for bovine respiratory disease and porcine respiratory disease, the same quinolone premix is processed under aseptic conditions at a labelled strength of 100 mg/mL (10% w/v) for cattle and swine, with a lower-strength 22.7 mg/mL (2.27% w/v) configuration used in small-animal injectable products. The addition ratio is selected to maintain solubility at pH 3.5–4.0 while avoiding excessive organic co-solvent load; lactic acid is preferred over phosphoric acid because phosphate anions can compete with quinolone for metal binding and produce particulate haze after dilution with isotonic saline in field administration. The manufacturing line is constructed from electropolished 316L stainless steel with a surface finish of Ra ≤ 0.6 µm; passivation with 1% citric acid is performed before every campaign because low-pH quinolone solutions leach free iron from unpassivated surfaces, producing a yellow-brown discolouration and increasing filter-loading pressure. Pre-dissolution is conducted as a 60-minute wetting step at 25°C, and incomplete dissolution is a known batch-to-batch failure mode that shows as sudden blinding of 0.22 µm PVDF sterilising filters and a 3–7% assay loss across the filtration train. Sterile filtration is used instead of terminal moist-heat sterilisation because the quinolone premix shows limited published stability data under saturated steam at 121°C; the fill is performed under Grade A laminar flow into depyrogenated Type I glass vials of 50 mL, 100 mL, and 250 mL, closed with bromobutyl rubber stoppers. Release testing is anchored to USP <71> sterility, USP <85> bacterial endotoxins, Ph. Eur. 5.1.1 and 21 CFR Part 522 for approved injectable enrofloxacin in cattle and swine, together with MRL compliance under Regulation (EU) No 37/2010. A critical operational boundary is that the solution must not be mixed with multi-valent cation diluents or infusion fluids containing calcium, magnesium, or iron, because quinolone-chelate precipitation occurs within minutes and cannot be re-dissolved by shaking.

Tablet Compression, Photo-Oxidation, and the 22.7 mg Dose Boundary

Tablet formulations for companion-animal dosing require the quinolone premix to be reduced to a particle size with d90 ≤ 250 µm before blending; otherwise the API segregates in the hopper and the content-uniformity acceptance value under USP <905> drifts above 15 at the low-dose end. The addition ratio is strength-dependent: a 22.7 mg tablet at a 500 mg core weight contains 4.54% w/w quinolone base, a 68 mg tablet contains 13.6% w/w, and a 136 mg tablet contains 27.2% w/w. Dibasic calcium phosphate dihydrate is not used as a filler in these core formulations because the calcium cation forms a poorly soluble quinolone complex and reduces dissolution below the compendial Q threshold. The downstream process is wet granulation rather than direct compression: povidone K30 is dissolved in an isopropanol-water mixture and sprayed into a high-shear granulator operating at impeller tip speed 5–8 m/s. The wet mass is dried in a fluid bed at inlet air 60°C until loss on drying is below 2.0% w/w, then lubricated with 1.0% w/w magnesium stearate for 3–5 minutes to avoid over-lubrication and dissolution failure. Compression is run on a rotary tablet press with pre-compression force 5 kN and main compression force 15–20 kN; tablet hardness is held at 8–12 kp to allow film coating without edge fracture. The finished tablets receive a light-protective HPMC-PEG film coat and are packed in aluminium/aluminium blister to limit photo-oxidation of the quinolone piperazinyl ring. Release testing is anchored to USP <711> dissolution using Apparatus II at 50 rpm in 900 mL of 0.1 M hydrochloric acid, Ph. Eur. 2.9.1 disintegration, and Ph. Eur. 2.2.46 related-substances HPLC. The operational boundary is storage: tablets exposed to 40°C and 75% relative humidity for more than one month can show discolouration and a related-substances increase; controlled room temperature storage at 20–25°C is specified.

For swine medicated feed applications, the quinolone premix is not added as raw API powder; a 10% w/w carrier-based premix is manufactured first by spraying a quinolone solution onto a fluidised carrier of corn cob and colloidal silica to reduce segregation and protect the API from direct pellet-mill heat exposure. The concentrated premix contains 100 g/kg quinolone base equivalent, and the final feed concentration is typically 50–100 mg/kg according to national prescribing guidelines and body-weight-adjusted dosing; the premix is diluted into feed at approximately 0.5–1.0 kg per tonne. The manufacturing equipment is a horizontal ribbon blender fitted with a spray bar and operated at 25 rpm; after API adsorption, 0.3–0.5% w/w mineral oil is added to suppress dust and improve carrier adhesion. Homogeneity is assessed by sampling 10 points across the blender and setting a release limit of coefficient of variation <5% for API assay. When the medicated feed is pelleted, pellet-conditioning temperatures above 80°C create a process boundary: the premix is preferably applied after pelleting through post-cooling liquid application, because published data for retention of this quinolone premix through longer steam-conditioning times above 85°C is limited. Compliance is anchored to Regulation (EU) 2019/6 veterinary medicinal product and medicated feed provisions, Regulation (EU) No 37/2010 Table 1 MRLs for swine tissues, VICH GL 18 residue-safety documentation, and HPLC assay of the premix per Ph. Eur. 2.2.46. The terminal finished product type is the 10% w/w premix packed in 20 kg polyethylene-lined paper bags or 25 kg fibre drums, intended solely for registered feed-mill dilution under veterinary prescription. Cross-contamination control is managed by validating cleanout of bucket elevators and dust extraction ducts; carryover of quinolone into non-target feed batches must remain below the segregation limit agreed in the national medicated-feed risk assessment.

When Soluble Granules Are Dosed Through Proportioner Pumps

Proportioner pump systems in poultry and porcine water lines impose a different set of failure modes from bulk drinking-water concentrates, because the dry soluble granules must first reconstitute rapidly at the stock-tank concentration and then pass through diaphragm or piston medicators without particle accumulation. The formulation addition ratio is typically 10% w/w quinolone base, with lactose monohydrate as the water-soluble bulking agent, citric acid as the acidifier, and sodium carbonate as the effervescent pH buffer. The granulation process is run in a high-shear granulator at impeller tip speed 5–8 m/s, followed by fluid-bed drying at 55°C until loss on drying is below 2.0% w/w; the dried granules are sized, and the fraction retained between 20 mesh and 60 mesh is held above 80% to prevent both fine-dust caking and slow dissolution of oversized granules. The reconstitution requirement is that a 10 g/L stock solution be clear within 5 minutes in water at 15°C; in hard water above 250 mg/L CaCO₃, the included citric acid and sodium carbonate buffer hold the solution pH below 4.5, thereby preventing quinolone-calcium precipitate formation that would otherwise clog proportioner inlet screens. Release testing is anchored to Ph. Eur. 2.2.32 loss on drying, Ph. Eur. 2.2.46 related-substances HPLC, and Ph. Eur. 2.2.1 clarity of solution. The terminal finished product type is a foil-laminate sachet of 100 g or 1 kg, nitrogen-flushed to reduce oxidative degradation. An operational boundary is chlorinated water: free chlorine above 4 ppm in the medicated stock solution accelerates oxidative attack on the quinolone piperazinyl ring, and published data for degradation kinetics under prolonged chlorine contact is limited; producers are therefore instructed to use dechlorinated or aged water when chlorine residuals exceed this threshold.

Hard-shell capsule filling for small-compounder and zoological dose-titration use applies the same quinolone premix at lower mechanical energy input and without granulation. The addition ratio is 2–20% w/w quinolone base in a direct blend with lactose monohydrate and 0.5% w/w magnesium stearate; the wide ratio range accommodates dose increments from 5 mg to 50 mg per capsule across species with different body-weight bands. The production process uses a semi-automatic low-speed capsule filler operating at 3,000–5,000 capsules/hour, with fill-weight variation controlled to ±5%; the terminal product type is size 2 or size 3 hard gelatin or HPMC capsule. Compliance for this configuration is less harmonised than for approved tablet or injectable dosage forms: industrial production is governed by national GMP for veterinary medicines, while extemporaneous compounding must follow national compounding regulations and 21 CFR Part 530 extra-label use restrictions where applicable. Published data for this specific capsule configuration is limited, so dose uniformity and stability must be validated per batch rather than extrapolated from tablet or injection stability profiles. The main process boundary is moisture: hard gelatin capsule shells become brittle below 40% relative humidity and tacky above 60% relative humidity, so the filling suite is held at 45–55% relative humidity and 20–25°C.